New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Alzheimer's breakthrough: Genetic link to gut disorders confirmed

Alzheimer's breakthrough: Genetic link to gut disorders confirmed

by Edith Cowan UniversityClusters of significantly enriched biological pathways for AD and GERD.aKEGG: Kyoto Encyclopedia of Genes and Genomes pathways:intestinal immune network
Gastroenterology February 19,2024
Alzheimer's breakthrough: Genetic link to gut disorders confirmed

Alzheimer's breakthrough: Genetic link to gut disorders confirmed

by Edith Cowan UniversityClusters of significantly enriched biological pathways for AD and GERD.aKEGG: Kyoto Encyclopedia of Genes and Genomes pathways:intestinal immune network
Gastroenterology February 19,2024
Upadacitinib superior to placebo in moderate-to-severe Crohn disease

Upadacitinib superior to placebo in moderate-to-severe Crohn disease

by Elana GotkineFor patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the&
Gastroenterology February 19,2024
Upadacitinib superior to placebo in moderate-to-severe Crohn disease

Upadacitinib superior to placebo in moderate-to-severe Crohn disease

by Elana GotkineFor patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the&
Gastroenterology February 19,2024
ChatGPT does not pass American College of Gastroenterology tests

ChatGPT does not pass American College of Gastroenterology tests

by Elana GotkineThe natural language processing model Chat Generative Pretrained Transformer (ChatGPT) does not pass the American College of Gastroenterology (ACG) Self-Assessment Tests, according to
Gastroenterology February 19,2024
ChatGPT does not pass American College of Gastroenterology tests

ChatGPT does not pass American College of Gastroenterology tests

by Elana GotkineThe natural language processing model Chat Generative Pretrained Transformer (ChatGPT) does not pass the American College of Gastroenterology (ACG) Self-Assessment Tests, according to
Gastroenterology February 19,2024
FDA approves first pill to treat moderate-to-severe Crohn's disease

FDA approves first pill to treat moderate-to-severe Crohn's disease

by Cara MurezPatients with Crohn's disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).Rinvoq is meant to treat adults
Gastroenterology February 19,2024
FDA approves first pill to treat moderate-to-severe Crohn's disease

FDA approves first pill to treat moderate-to-severe Crohn's disease

by Cara MurezPatients with Crohn's disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).Rinvoq is meant to treat adults
Gastroenterology February 19,2024
ACG issues guideline for management of upper GI bleeding

ACG issues guideline for management of upper GI bleeding

(HealthDay)—In an American College of Gastroenterology clinical guideline, published in the May issue of theAmerican Journal of Gastroenterology, recommendations are presented for the mana
Gastroenterology February 19,2024
ACG issues guideline for management of upper GI bleeding

ACG issues guideline for management of upper GI bleeding

(HealthDay)—In an American College of Gastroenterology clinical guideline, published in the May issue of theAmerican Journal of Gastroenterology, recommendations are presented for the mana
Gastroenterology February 19,2024
Cancer-targeting virus therapy combined with radiation more effective against brain cancer than either one alone

Cancer-targeting virus therapy combined with radiation more effective against brain cancer than either one alone

by Gillian Rutherford,University of AlbertaResearchers Mary Hitt (left) and Quinn Storozynsky found that using a cancer-targeting virus therapy at the same time as radiation gives more benefit t
Oncology February 19,2024
Cancer-targeting virus therapy combined with radiation more effective against brain cancer than either one alone

Cancer-targeting virus therapy combined with radiation more effective against brain cancer than either one alone

by Gillian Rutherford,University of AlbertaResearchers Mary Hitt (left) and Quinn Storozynsky found that using a cancer-targeting virus therapy at the same time as radiation gives more benefit t
Oncology February 19,2024
A cell surface marker for identifying tumor-initiating cells in pancreatic cancer

A cell surface marker for identifying tumor-initiating cells in pancreatic cancer

by Kumamoto UniversityROR1 is a cell surface receptor that promotes hyperproliferation, metastasis, and relapse in PDAC when highly expressed. Suppressing ROR1 reduces PDAC growth. Credit: Masaya
Oncology February 19,2024
A cell surface marker for identifying tumor-initiating cells in pancreatic cancer

A cell surface marker for identifying tumor-initiating cells in pancreatic cancer

by Kumamoto UniversityROR1 is a cell surface receptor that promotes hyperproliferation, metastasis, and relapse in PDAC when highly expressed. Suppressing ROR1 reduces PDAC growth. Credit: Masaya
Oncology February 19,2024
Endoscopy within six hours does not lower mortality in GI bleed

Endoscopy within six hours does not lower mortality in GI bleed

(HealthDay)—Endoscopy within six hours versus six to 24 hours after consultation is not associated with lower 30-day mortality in patients with acute upper gastrointestinal bleeding who are at high ri
Gastroenterology February 19,2024
Endoscopy within six hours does not lower mortality in GI bleed

Endoscopy within six hours does not lower mortality in GI bleed

(HealthDay)—Endoscopy within six hours versus six to 24 hours after consultation is not associated with lower 30-day mortality in patients with acute upper gastrointestinal bleeding who are at high ri
Gastroenterology February 19,2024
Opioids frequently prescribed to patients with cirrhosis

Opioids frequently prescribed to patients with cirrhosis

by Elana Gotkine HealthDay ReporterOpioids are frequently prescribed to patients with cirrhosis, often without a pain diagnosis, according to a research letter published online Dec. 8 inClinical
Gastroenterology February 19,2024
Opioids frequently prescribed to patients with cirrhosis

Opioids frequently prescribed to patients with cirrhosis

by Elana Gotkine HealthDay ReporterOpioids are frequently prescribed to patients with cirrhosis, often without a pain diagnosis, according to a research letter published online Dec. 8 inClinical
Gastroenterology February 19,2024
Risk for adverse events not increased after COVID-19 vaccine in IBD

Risk for adverse events not increased after COVID-19 vaccine in IBD

(HealthDay)—Individuals with inflammatory bowel disease (IBD) do not have an increased risk for adverse events (AEs) after the mRNA COVID-19 vaccination, according to a study published online May 25 i
Gastroenterology February 19,2024
Risk for adverse events not increased after COVID-19 vaccine in IBD

Risk for adverse events not increased after COVID-19 vaccine in IBD

(HealthDay)—Individuals with inflammatory bowel disease (IBD) do not have an increased risk for adverse events (AEs) after the mRNA COVID-19 vaccination, according to a study published online May 25 i
Gastroenterology February 19,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com